Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Oncorus, Inc. (ONCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
06/09/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Approval of Plan. The Board of Directors of the Company has adopted this Plan and presented the Plan to the Company’s stockholders to take action on the Plan. If the Plan is adopted by the requisite vote of the Company’s stockholders, the Plan shall constitute the adopted Plan of the Company. 2. Certificate of Dissolution. Subject to Section 14 hereof, after the stockholders of the Company approve the dissolution of the Company, the Company shall file with the Secretary of State of the State of Delaware a certificate of dissolution in accordance with the DGCL at such time as determined by the Company in its sole discretion . 3. Cessation of Business Activities. After the Effective Time, the Company shall not engage in any business activities except to the extent necessary to preserve the v..."
06/01/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Investor Contact:"
05/18/2023 8-K Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation o...
05/05/2023 8-K Quarterly results
05/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/24/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Oncorus, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Year Ended December 31, December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 15,708 $ 14,276 $ 54,744 $ 44,682 General and administrative 5,072 5,586 21,793 20,136 Total operating expenses 20,780 19,862 76,537 64,818 Loss from operations Other income : Other income 285 210 Interest expense — — Interest income 309 27 911 65 Total other income , net 19 56 Net loss $ $ $ $ Comprehensive loss: Net unrealized gain on investments 21 Comprehensive loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average number of common shares 25,973 25,814 25,924 25,320 Oncorus, Inc. Selected Condensed Consolidated Balance Sheet Data Cash and cash equivalents..."
03/14/2023 8-K Regulation FD Disclosure  Interactive Data
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
11/30/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
09/14/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE is entered into as of this 13th day of September, 2022, by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company , and ONCORUS, INC., a Delaware corporation . RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of May 10, 2016 as amended by that certain First Amendment to Lease dated as of November 17, 2016 , whereby Tenant leases certain premises from Landlord located on the fourth floor of the building at 50 Hampshire Street in Cambridge, Middlesex County, Massachusetts ; B. WHEREAS, Landlord and Tenant desire to amend the Term Expiration Date under the Existing Lease; and C. WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the condi..."
08/05/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/05/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "WARRANT TO PURCHASE SHARES OF COMMON STOCK Company: Oncorus, Inc., a Delaware corporation Class of Shares: Common Stock, $0.0001 par value per share Number of Shares: A number equal to 2.95% of aggregate Term Loan advances actually made to the Company divided by the Warrant Price as in effect from time to time Warrant Price: $1.5126 Issue Date: April 1, 2022 Expiration Date: 10 years from the Issue Date Loan Agreement: This Warrant to Purchase shares of Common Stock is issued in connection with, and as consideration for the commitments pursuant to, that certain Loan and Security Agreement of even date herewith among the Company and certain other borrowers from time to time party thereto, K2 HealthVentures LLC, as administrative agent for lender, Ankura Trust Company, LLC, as collateral age...",
"LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT dated as of April 1, 2022 is entered into among ONCORUS, INC., a Delaware corporation , and each other Person party hereto as a borrower from time to time , K2 HEALTHVENTURES LLC as a lender, and the other lenders from time to time party hereto , K2 HEALTHVENTURES LLC, as administrative agent for Lenders , and ANKURA TRUST COMPANY, LLC, as collateral agent for Lenders . AGREEMENT Borrower Representative, each Loan Party from time to time party hereto, Administrative Agent, Collateral Trustee and Lenders hereby agree as follows: 1. ACCOUNTING AND OTHER TERMS Accounting terms not defined in this Agreement shall be construed in accordance with GAAP, and calculations and determinations shall be made following GAAP, consistently appli...",
"Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway -Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA and the clinical development of its IV administered vRNA/LNP product candidate, ONCR-021, and other pipeline programs- -Relocation of corporate headquarters to Andover facility- -Cash runway extended into early 2024- CAMBRIDGE, Mass., April 5, 2022"
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2022 8-K Quarterly results
01/26/2022 8-K Other Events  Interactive Data
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "3 ONCR-177 IL-12, FLT3L, CCL4,"
11/19/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Company”), in connection with the offering by the Company of up to $50,000,000 of the Company’s common stock, par value $0.0001 per share, , pursuant to a Registration Statement on Form S-3 , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act",
"OPEN MARKET SALE AGREEMENT November 19, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022",
"Total $ 164,040"
11/12/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Investor Contact:"
11/09/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Oncorus Announces Details of Upcoming ONCR-177 Phase 1 Initial Clinical Data Presentation at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting -- Company to host conference call and webcast on Friday, November 12, 2021 at 8:30 a.m. ET -- CAMBRIDGE, Mass., November 9, 2021"
11/03/2021 8-K Quarterly results
Docs: "Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates  To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming Society for Immunotherapy of Cancer’s 36th Annual Meeting on November 12th  Completed Pre-IND meeting and initiating GLP IND-enabling safety and tolerability studies for lead intravenously administered Synthetic viral RNA immunotherapy candidate, ONCR-021 ; plans to submit an IND for ONCR-021 in the first half of 2023  Continues non-GLP safety and tolerability studies for second Synthetic vRNA immunotherapy candidate ONCR-788  First phase of GMP clinical manufacturing facility completed, ..."
08/04/2021 8-K Quarterly results
Docs: "Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights"
07/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 27, 2021 Oncorus, Inc. Delaware 001-39575 47-3779757 File Number) Identification No.) 50 Hampshire Street, Suite 401 Cambridge, Massachusetts 02139 Registrant's Telephone Number, Including Area Code: 320-6400 Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 u...",
"Investor Contact:"
06/21/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy